Context. T-690 (Takeda) is an oral GCS inhibitor that is brain-penetrant, non-basic, and non-competitive with UDP-glucose. We recently highlighted a glucosylceramide synthase (GCS, aka CGT) inhibitor in Ph. III (Sanofi’s venglustat ). GCS inhibition may reduce glycosphingolipid levels downstream of its product, glucosylceramide (GlcCer). GCS [...]
2 minute read
Mar. 12, 2022
T-690: an oral GCS inhibitor
T-690
oral GCS inhibitor Preclinical, neurodegeneration scaffold hop from prev. reported GCS inhibitor J. Med. Chem. Takeda
Loading...
